

Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed diagnosis of non-squamous, non-small cell lung cancer (NSCLC) - have advanced disease, defined as

•either stage IV disease, stage IIIB disease not amenable to definitive therapy, or recurrent disease - no prior systemic treatment for metastatic disease - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - additional inclusion criteria (study staff will review)

Conditions & Interventions

Interventions:

Biological: Bevacizumab, Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Osimertinib

Conditions:

Cancer

Keywords:

Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, NSCLC, Stage III or Stage IV Lung Cancer

More Information

Description: This trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs and has a change (mutation) in a gene called EGFR. Sometimes, mutations in this gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly.

Study Contact: Kristen Nelson - knelso65@fairview.org

Principal Investigator: Nicole Hartung

IRB

Number: MMCORC040

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.